Medicine Supply Notification: Supply issues with multiple GLP-1 RA products

Department of Health and Social Care (DHSC) has issued a medicine supply notification for Semaglutide (Ozempic®) 0.25mg, 0.5mg and 1mg solution for injection in a pre-filled pen Dulaglutide (Trulicity®) 0.75mg, 1.5mg, 3mg and 4.5mg solution for injection in a prefilled pen Liraglutide (Victoza®) 6mg/ml solution for injection in a pre-filled pen.

MSN/2024/031

Tier 3 – high impact

Date of issue: 18th March 2024

Semaglutide

• Semaglutide (Ozempic®) 0.25mg and 1mg solution for injection in a pre-filled pen are available but will have intermittent supply throughout 2024. New patient initiations cannot be supported.
• Semaglutide (Ozempic®) 0.5mg solution for injection in a pre-filled pen is out of stock until early June 2024. This product will then have intermittent supply until the end of 2024. New patient initiations cannot be supported.
• Semaglutide (Rybelsus®) 3mg, 7mg and 14mg tablets are available and can support increased demand for both new patient initiations and any patients unable to obtain their existing GLP-1 RA therapy

Dulaglutide

• Dulaglutide (Trulicity®) 0.75mg, 1.5mg, 3mg and 4.5mg solution for injection in a pre-filled pen are available but will have intermittent supply throughout 2024. New patient initiations cannot be supported.

Liraglutide

• Liraglutide (Victoza®) 6mg/ml solution for injection in a pre-filled pen is out of stock until end of 2024.

Exenatide

• Exenatide (Bydureon BCise®) 2mg/0.85ml prolonged-release pre-filled pens remain available for patients stabilised on therapy but are not able to support new patient initiations.
• Exenatide (Byetta®) 5micrograms/0.02ml and 10micrograms/0.04ml pre-filled pens will be discontinued at the end of March 2024.

Tirzepatide

• Tirzepatide (Mounjaro® Kwikpens®) 2.5mg/0.6ml and 5mg/0.6ml solution for injection 2.4ml pre-filled pens (containing 4 doses) are now available and can support both new patient initiations and any patients unable to obtain their existing GLP-1 RA therapy.
• Higher strengths of tirzepatide (Mounjaro® Kwikpens®) will become available in the coming months (7.5mg/0.6ml, 10mg/0.6ml, 12.5mg/0.6ml and 15mg/0.6ml solution for injection 2.4ml pre-filled pens).

A copy of this medicine supply notification, including further information, has been sent to all pharmacy NHS email addresses.

DHSC and NHSE/I have now launched an online Medicines Supply Tool, which provides up to date information about medicine supply issues. The contents of these MSNs can now be viewed on the Tool.

The Tool also details any changes to resupply dates and updates to the entries.

To access the Tool you will need  an NHS email address. Once set up and logged in, you will be able to access it online.

New shortages not listed on the SPS website, can be reported using our shortage reporting tool.